INP51 Antibody

What is INP51 and why is it significant in research?

INP51 (also referred to as Inp51p) is a 946 amino acid phosphatase that functions as an inositol polyphosphate 5-phosphatase in yeast. Its structure contains both carboxyl- and amino-terminal regions that share similarities with mammalian inositol polyphosphate 5-phosphatases and yeast SAC1, resembling the structure of the mammalian 5-phosphatase synaptojanin . INP51 is significant in research because it plays a crucial role in phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) homeostasis and regulates cell wall integrity, hyphal formation, and virulence in fungi like Candida albicans . Understanding INP51 function contributes to our knowledge of phosphoinositide signaling and fungal pathogenesis.

How should INP51 antibodies be validated before experimental use?

INP51 antibodies should be validated following the "five pillars" of antibody characterization recommended by the International Working Group for Antibody Validation :

• Genetic validation: Test antibody specificity using inp51 knockout or knockdown models, which should show diminished or absent signal compared to wild-type samples.

• Orthogonal validation: Compare antibody-based detection results with antibody-independent methods (e.g., mass spectrometry or RNA-seq).

• Independent antibody validation: Use multiple antibodies targeting different epitopes of INP51 to confirm consistent localization and expression patterns.

• Expression validation: Test antibody performance in systems with induced overexpression of INP51.

• Immunoprecipitation-mass spectrometry: Confirm that the antibody captures the intended target by analyzing immunoprecipitated proteins using mass spectrometry.

Researchers should document validation using at least two of these methods before proceeding with experimental applications .

What are the key structural features of INP51 that influence antibody selection?

When selecting antibodies against INP51, researchers should consider these key structural features:

• The NPF (Asn-Pro-Phe) motif: This domain is critical for interaction with EH domain-containing proteins like Irs4p . Antibodies targeting this region may disrupt protein-protein interactions.

• Phosphatase catalytic domain: Antibodies targeting this region may affect enzymatic activity or substrate binding.

• Similarities to mammalian inositol polyphosphate 5-phosphatases: Researchers should verify specificity to prevent cross-reactivity with similar phosphatases.

• Yeast-specific epitopes: When designing antibodies for yeast INP51, select epitopes that differ from mammalian homologs to ensure specificity when using in mixed systems.

Optimal antibody selection should balance these considerations based on experimental objectives.

What are the recommended protocols for using INP51 antibodies in immunoprecipitation studies?

For optimal INP51 immunoprecipitation studies, follow this methodological approach:

• Cell lysis preparation:

  • For Saccharomyces cerevisiae or Candida albicans, use glass bead lysis in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, with protease and phosphatase inhibitors.

  • Centrifuge at 14,000×g for 15 minutes at 4°C to remove cell debris.

• Pre-clearing:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C.

  • Remove beads by centrifugation to reduce non-specific binding.

• Immunoprecipitation:

  • Add validated INP51 antibody (2-5 μg per 1 mg of protein lysate).

  • Incubate overnight at 4°C with gentle rotation.

  • Add protein A/G beads and incubate for 2-3 hours.

  • Wash 4-5 times with lysis buffer.

• Elution and analysis:

  • Elute bound proteins by boiling in SDS-PAGE sample buffer.

  • Analyze by Western blotting using a different INP51 antibody or by mass spectrometry.

This protocol enables detection of INP51-interacting proteins such as Irs4p, which has been demonstrated to interact with INP51 through its NPF motif .

How can INP51 antibodies be used to study phosphoinositide signaling pathways?

INP51 antibodies can be powerful tools for investigating phosphoinositide signaling through these methodological approaches:

• Pathway component localization:

  • Use immunofluorescence with INP51 antibodies in combination with markers for other pathway components to determine spatial organization.

  • Co-localization studies with PI(4,5)P2 sensors can reveal functional relationships.

• Pathway regulation analysis:

  • Immunoprecipitate INP51 followed by Western blotting for post-translational modifications to study regulation mechanisms.

  • Use proximity ligation assays to detect interactions between INP51 and other signaling proteins in situ.

• Activity correlation:

  • Combine INP51 immunodetection with quantitative PI(4,5)P2 level measurements to correlate enzyme presence with substrate levels.

  • Research has shown that inp51 null mutants exhibit a 2-4-fold increase in PI(4,5)P2 and inositol 1,4,5-trisphosphate levels, while overexpression reduces PI(4,5)P2 by approximately 35% .

• Signaling pathway manipulation:

  • Use INP51 antibodies to deplete or inhibit the enzyme in cell extracts to study downstream effects on signaling cascades.

  • Monitor effects on the cell wall integrity pathway through Mkc1p phosphorylation, which is overactivated in inp51 mutants .

What considerations should be made when using INP51 antibodies for immunohistochemistry?

When using INP51 antibodies for immunohistochemistry on fungal samples, consider these methodological factors:

• Fixation optimization:

  • Test multiple fixation methods (e.g., paraformaldehyde, methanol) as phosphatases can be sensitive to fixation conditions.

  • For fungal cells, a combination of 4% paraformaldehyde with partial cell wall digestion using zymolyase may improve antibody accessibility.

• Epitope accessibility:

  • Include antigen retrieval steps optimized for cell wall-containing organisms.

  • For Candida albicans, mild cell wall digestion with chitinase may improve antibody penetration while preserving hyphal structures.

• Controls and validation:

  • Always include inp51 knockout strains as negative controls.

  • Use orthogonal detection methods to confirm localization patterns.

  • Multiple antibodies against different INP51 epitopes should show consistent localization patterns.

• Visualization considerations:

  • For co-localization with cell wall components, consider counterstaining with calcofluor white or wheat germ agglutinin.

  • When studying hyphal formation, examine INP51 distribution along hyphal walls during growth, as abnormal chitin distribution has been observed in inp51 mutants .

How can phosphoproteomics be integrated with INP51 antibody research to understand signaling networks?

Integrating phosphoproteomics with INP51 antibody research requires a systematic approach:

• Experimental design strategy:

  • Compare phosphoproteomes between wild-type and inp51 mutant strains to identify differentially phosphorylated proteins.

  • Use SILAC (Stable Isotope Labeling with Amino acids in Cell culture) or TMT (Tandem Mass Tags) for quantitative comparison.

• Sample preparation workflow:

  • Immunoprecipitate INP51 and its interacting partners using validated antibodies.

  • Perform phosphopeptide enrichment using TiO2 or IMAC (Immobilized Metal Affinity Chromatography).

  • Process samples for mass spectrometry analysis.

• Data integration methods:

  • Correlate INP51 activity (measured by immunoblotting) with changes in phosphorylation of proteins in the cell wall integrity pathway.

  • Map identified phosphoproteins to pathways influenced by PI(4,5)P2 levels.

  • Create network models that connect INP51 activity to observed phenotypes like hyphal formation and cell wall integrity.

• Validation approach:

  • Confirm key phosphorylation events using phospho-specific antibodies.

  • Perform site-directed mutagenesis of identified phosphorylation sites to assess functional consequences.

  • Use proximity-dependent labeling techniques with INP51 antibodies to validate protein interactions in living cells.

What are the best approaches for studying INP51 dynamics during environmental stress responses?

To investigate INP51 dynamics during stress responses, implement these advanced methodological approaches:

• Real-time imaging techniques:

  • Use fluorescently tagged anti-INP51 antibody fragments (Fabs) for live-cell imaging.

  • Combine with fluorescent PI(4,5)P2 probes to simultaneously track substrate and enzyme.

• Stress response experimental setup:

  • For cold stress: Monitor INP51 localization during temperature shifts, as inp51 deletion confers cold tolerance below 15°C .

  • For cell wall stress: Track INP51 during treatment with agents like Congo red or Calcofluor white that challenge cell wall integrity.

  • For hyphal induction conditions: Examine INP51 distribution during morphological transitions.

• Quantitative analysis methods:

  • Measure INP51 protein levels by quantitative immunoblotting during stress response time courses.

  • Correlate with PI(4,5)P2 levels measured by lipid extraction and analysis.

  • Quantify localization changes using digital image analysis of immunofluorescence data.

• Integrated omics approach:

  • Pair INP51 antibody-based proteomics with transcriptomics and lipidomics during stress responses.

  • Develop computational models that predict INP51 behavior based on multi-omics data.

How can CRISPR/Cas9 technology be combined with INP51 antibodies for functional studies?

Integrating CRISPR/Cas9 technology with INP51 antibody research enables sophisticated functional analyses:

• Epitope tagging strategy:

  • Use CRISPR/Cas9 to add epitope tags to endogenous INP51, enabling detection with commercial tag antibodies.

  • Insert fluorescent protein tags at the C-terminus to preserve the NPF motif while allowing live visualization.

• Domain-specific mutant generation approach:

  • Create precise mutations in functional domains (e.g., catalytic site, NPF motif) to study domain-specific functions.

  • Use INP51 antibodies to confirm expression of the mutated protein and analyze changes in interacting partners.

• Inducible degradation system implementation:

  • Engineer CRISPR-based auxin-inducible degron (AID) tags on INP51.

  • Use antibodies to monitor degradation kinetics and correlate with phenotypic changes.

  • This approach allows temporal control of INP51 depletion without genetic knockouts.

• Multiplexed gene regulation:

  • Simultaneously target INP51 and interacting partners like IRS4 with CRISPR interference or activation.

  • Use antibodies against both proteins to quantify expression changes and effects on complex formation.

  • This method helps dissect pathway relationships and redundancies.

How should researchers address potential cross-reactivity when using INP51 antibodies?

To address cross-reactivity concerns with INP51 antibodies, follow this systematic approach:

• Specificity testing protocol:

  • Test antibodies on inp51 knockout strains as negative controls.

  • Perform peptide competition assays using the immunizing peptide.

  • Test antibodies on closely related phosphatases (e.g., other phosphoinositide phosphatases) to assess cross-reactivity.

• Antibody characterization steps:

  • Determine if the antibody recognizes denatured (Western blot) and/or native (immunoprecipitation) protein.

  • Test multiple antibody dilutions to find optimal signal-to-noise ratio.

  • Characterize using at least two of the five pillars of antibody validation approaches .

• Cross-reactivity mitigation strategies:

  • Pre-absorb antibodies with lysates from inp51 knockout strains.

  • Use highly specific monoclonal antibodies when available.

  • Consider recombinant antibody fragments with enhanced specificity.

• Data verification approach:

  • Always confirm key findings using orthogonal detection methods.

  • Use multiple antibodies targeting different epitopes of INP51.

  • Include appropriate positive and negative controls in all experiments.

What are the potential confounding factors when interpreting INP51 immunolocalization data?

When interpreting INP51 immunolocalization data, be aware of these potential confounding factors and their methodological solutions:

• Fixation artifacts:

  • Cross-validation: Compare multiple fixation methods to distinguish true localization from artifacts.

  • Live-cell validation: When possible, confirm fixed-cell observations with live-cell imaging using tagged INP51.

• Cell wall interference:

  • Controlled digestion: Optimize cell wall digestion protocols to balance antibody accessibility with preservation of subcellular structures.

  • Comparison control: Include samples with and without cell wall digestion to identify any localization changes induced by the procedure.

• Background signal:

  • Blocking optimization: Test multiple blocking agents (BSA, serum, casein) to reduce non-specific binding.

  • Secondary-only controls: Include controls with only secondary antibody to identify non-specific binding.

• Growth condition variations:

  • Standardized conditions: Maintain consistent growth conditions, as INP51 localization may change with growth phase or stress.

  • Environmental documentation: Carefully document and report all growth parameters, as inp51 mutants show phenotypic differences under specific conditions like cold temperature or cell wall stress .

How can researchers reconcile contradictory data from different INP51 antibody-based experiments?

When faced with contradictory INP51 antibody data, employ this systematic reconciliation approach:

• Antibody characteristics assessment:

  • Compare epitopes: Determine if antibodies recognize different epitopes that might be differentially accessible in various contexts.

  • Validation strength: Evaluate the extent of validation for each antibody using the five pillars framework .

  • Batch variations: Check for lot-to-lot variations that might affect antibody performance.

• Experimental conditions comparison:

  • Buffer composition: Evaluate differences in lysis or immunoprecipitation buffers that might affect INP51 conformation or interactions.

  • Cell growth differences: Compare growth conditions, as INP51 function varies with temperature and stress conditions .

  • Sample preparation variations: Consider differences in cell lysis, fixation, or protein extraction methods.

• Biological context evaluation:

  • Cell type differences: INP51 may have different interacting partners or modifications in different yeast strains or species.

  • Growth phase: INP51 expression and localization may vary with cell cycle or growth phase.

  • Environmental factors: Consider the impact of media composition, pH, or temperature on INP51 behavior.

• Integrative data analysis:

  • Weigh evidence based on validation strength: Prioritize results from antibodies validated by multiple methods.

  • Combine multiple detection methods: Integrate data from Western blotting, immunofluorescence, and mass spectrometry.

  • Consider biological replicates: Evaluate reproducibility across independent experiments.

How can INP51 antibodies be utilized in fungal pathogenesis research?

INP51 antibodies offer valuable tools for investigating fungal pathogenesis through these methodological approaches:

• Virulence mechanism investigation:

  • Track INP51 expression and localization during host-pathogen interactions using immunohistochemistry.

  • Compare INP51 levels between virulent and attenuated strains using quantitative immunoblotting.

  • Research has shown that inp51 mutant strains demonstrate attenuated virulence in mouse models of disseminated candidiasis .

• In vivo infection dynamics:

  • Use fluorescently labeled INP51 antibodies to track pathogen behavior in tissue samples.

  • Correlate INP51 activity with hyphal formation in vivo, as inp51 mutants show impaired hyphal formation and abnormal chitin distribution .

• Drug target validation:

  • Employ INP51 antibodies to confirm target engagement of potential antifungal compounds.

  • Monitor changes in INP51 localization or interactions following drug treatment.

• Host-pathogen interface analysis:

  • Study INP51 redistribution during contact with host cells using immunofluorescence.

  • Investigate phosphoinositide dynamics at infection sites by combining INP51 antibody staining with phosphoinositide sensors.

What are the prospects for developing recombinant INP51 antibodies with enhanced specificity?

The development of recombinant INP51 antibodies offers significant advantages for research applications:

• Recombinant antibody technology selection:

  • Single-chain variable fragments (scFvs): Smaller size allows better tissue penetration and epitope accessibility.

  • Antigen-binding fragments (Fabs): Provide improved stability compared to scFvs while maintaining specificity.

  • Nanobodies: Single-domain antibodies derived from camelid antibodies offer exceptional stability and small size.

• Epitope targeting strategy:

  • Focus on yeast-specific regions that differ from mammalian homologs.

  • Target functional domains like the catalytic site or the NPF motif for function-blocking antibodies.

  • Design complementary antibodies against different epitopes for validation purposes.

• Characterization requirements:

  • Extensive validation using the five pillars approach recommended for antibody characterization .

  • Documentation of specificity across multiple assay conditions.

  • Publication of sequences to enable reproducibility and further optimization by other researchers.

• Application-specific optimization:

  • Engineer recombinant antibodies with tags for specific applications (fluorescent proteins for imaging, affinity tags for purification).

  • Develop antibodies optimized for particular applications like immunoprecipitation or immunohistochemistry.

  • The approach used by NeuroMab could be adapted, where ~1,000 clones are screened in parallel ELISAs followed by application-specific testing .